Kissei Pharmaceutical Co., Ltd. announced the new launch of Icelty\u00ae Tablets 100mg for the treatment of uterine fibroids on March 19, 2026. The manufacturing and marketing approval was obtained on December 22, 2025.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4547-20260319-01.pdf","jir_short_summary":"Kissei Pharmaceutical Co., Ltd. announced the new launch of Icelty\u00ae Tablets 100mg for the treatment of uterine fibroids on March 19, 2026. The manufacturing and marketing approval was obtained on December 22, 2025.","jir_summary":"### Product Overview and Launch\nKissei Pharmaceutical Co., Ltd. newly launched Icelty\u00ae Tablets 100mg (generic name: Linzagolix Olamine), an orally administrable GnRH antagonist for the treatment of uterine fibroids, on March 19, 2026. This product aims to improve symptoms of uterine fibroids, and development for endometriosis within Japan is also underway. Manufacturing and marketing approval was obtained on December 22, 2025.\n\n### Overseas Expansion and Social Significance\nOverseas, Theramex UK Ltd. markets the product in Europe, where the European Medicines Agency (EMA) has also approved an additional indication for endometriosis. Technology licensees in Taiwan, South Korea, and Canada are advancing development. Uterine fibroids affect over 70% of women, particularly in their 30s and 40s, significantly impacting quality of life and social activities. Kissei Pharmaceutical operates the disease awareness website \u201cbe loving\u201d and is committed to improving access to medical care.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #NewProductLaunch, #UterineFibroidTreatment","jir_key_figures":"Manufacturing and Marketing Approval Date: 2025-12-22\nDrug Price Standard Listing Date: 2026-03-18\nLaunch Date: 2026-03-19","jir_meta_title":"Kissei Pharmaceutical Launches Icelty\u00ae Tablets 100mg for Uterine Fibroid Treatment on March 19, 2026","jir_meta_description":"Kissei Pharmaceutical Co., Ltd. announced the new launch of Icelty\u00ae Tablets 100mg for uterine fibroid treatment on March 19, 2026. Manufacturing and marketing approval was obtained on December 22, 2025. The document also covers domestic and international development status and disease awareness activities.","jir_og_title":"Kissei Pharmaceutical Announces New Launch of Icelty\u00ae Tablets 100mg for Uterine Fibroid Treatment","jir_og_description":"Kissei Pharmaceutical Co., Ltd. launched Icelty\u00ae Tablets 100mg for uterine fibroid treatment on March 19, 2026. Focus on overseas expansion and disease awareness activities.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-35375","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n